An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Relapsing or Refractory Chronic Lymphocytic Leukemia
NCT01488162 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 327
Last updated 2017-03-22
Summary
This multi-center, prospective, observational study will describe the management of relapsing or refractory chronic lymphocytic leukemia (CLL) patients. Data will be collected for 2 years.
Conditions
- Lymphocytic Leukemia, Chronic
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Clinical Trials · Hoffmann-La Roche
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-04-04
- Primary Completion
- 2016-10-24
- Completion
- 2016-10-24
Countries
- France
Study Locations
More Related Trials
-
A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas
NCT01153971 ·Status: COMPLETED ·Phase: PHASE2
-
Tolerance and Efficacy of Subcutanous Low Doses Rituximab for CLL Consolidation Treatment
NCT01521689 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab
NCT01461928 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)
NCT02533401 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
NCT01144364 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL)
NCT00718549 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma
NCT00269113 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Rituximab (MabThera) in Combination With Chemotherapy in Participants With CD20-Positive B-Cell Chronic Lymphocytic Leukemia
NCT01609023 ·Status: COMPLETED
-
A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia
NCT01292603 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL
NCT00858117 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess the Efficacy of Rituximab (MabThera) in First Line Treatment of Chronic Lymphocytic Leukemia (CLL)
NCT00545714 ·Status: COMPLETED ·Phase: PHASE2
-
An Observational Study of MabThera/Rituxan (Rituximab) Plus Chemotherapy As First-Line Treatment in Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
NCT01340443 ·Status: COMPLETED
-
An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Lymphoma
NCT01609036 ·Status: TERMINATED
-
A Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma.
NCT01144403 ·Status: TERMINATED ·Phase: PHASE2
-
Primary Rituximab and Maintenance
NCT00140582 ·Status: COMPLETED ·Phase: PHASE3
-
Phase II Study of High-Dose Rituximab in High-Risk Chronic Lymphocytic Leukemia Patients in Suboptimal Response After Induction Immunochemotherapy
NCT01625741 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma
NCT01649856 ·Status: COMPLETED ·Phase: PHASE3
-
Relmacabtagene Autoleucel in Patients With LBCL
NCT06142175 ·Status: RECRUITING
-
Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis
NCT00553943 ·Status: COMPLETED ·Phase: PHASE2
-
Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue
NCT01611259 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of MabThera (Rituximab) in Primary Central Nervous System Lymphoma.
NCT00517699 ·Status: TERMINATED ·Phase: PHASE2
-
Safety and Efficacy of Revlimid® (Lenalidomide) With Mabthera® (Rituximab) in Non-Hodgkin's Lymphoma
NCT01939327 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma
NCT01200758 ·Status: COMPLETED ·Phase: PHASE3
-
Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery
NCT02160015 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
NCT01938001 ·Status: COMPLETED ·Phase: PHASE3